The latest price target for ResMed (NYSE:RMD) was reported by Piper Sandler on January 10, 2025. The analyst firm set a price target for $252.00 expecting RMD to rise to within 12 months (a possible 1.70% upside). 33 analyst firms have reported ratings in the last year.

The latest analyst rating for ResMed (NYSE:RMD) was provided by Piper Sandler, and ResMed initiated their neutral rating.

The last upgrade for ResMed Inc happened on October 27, 2023 when Morgan Stanley raised their price target to $169. Morgan Stanley previously had an equal-weight for ResMed Inc.

The last downgrade for ResMed Inc happened on September 18, 2024 when Wolfe Research changed their price target from N/A to $180 for ResMed Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ResMed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ResMed was filed on January 10, 2025 so you should expect the next rating to be made available sometime around January 10, 2026.

While ratings are subjective and will change, the latest ResMed (RMD) rating was a initiated with a price target of $0.00 to $252.00. The current price ResMed (RMD) is trading at is $247.79, which is within the analyst’s predicted range.